Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.9894
- Book/Share 38.2151
- PB 8.1562
- Debt/Equity 0.5957
- CurrentRatio 0.7761
- ROIC 0.3599
- MktCap 1385478304840.9907
- FreeCF/Share 14.1116
- PFCF 22.0839
- PE 13.3532
- Debt/Assets 0.1976
- DivYield 0.0348
- ROE 0.6695
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
News
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Novo Nordisk: The Market Hasn't Given It Enough Respect
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Negative
Healthcare stocks have lagged the S&P 500, with Novo Nordisk already hit hard by intense competition from Eli Lilly. Despite recent setbacks and a decelerating growth outlook, Novo Nordisk's valuation now reflects steep pessimism, suggesting the downside appears limited. Novo Nordisk's robust brand, R&D, and profit margins provide a significant moat, even as competition in the GLP-1 market intensifies.
Read More
Novo Nordisk's Moat Is Deeper Than You Think
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally. Obesity drug sales surged 65% YoY in Q1-FY25, driving total revenue growth of 18% and free cash flow of $1.38 billion. The company projects FY25 free cash flow between $8.14–$9.59 billion, supported by 48.43% EBIT margins and expanding manufacturing capacity.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (July 2025)
Published: July 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and almost $5 billion in the first quarter of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
Published: July 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Fangzhou Inc., a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company.
Read More
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Read More
3 Ridiculously Discounted Growth Stocks to Buy Now
Published: July 16, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Buying beaten-down stocks allows investors to purchase high-quality companies at bargain prices, capitalizing on market overreactions.
Read More
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
Read More
Novo Nordisk: The Market Doesn't Get It
Published: July 11, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk remains dominant in diabetes and obesity care, with strong growth and expanding market share despite recent investor concerns. The company's pipeline, especially the oral GLP-1 and Alzheimer's trial, offers significant long-term upside. The company needs to grow its top-line at mid-% to justify its current valuation. By assuming the market growth rate, the company is massively undervalued.
Read More
Smart Money Going in Senior Health: Key Stocks in Elderly Care
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Read More
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Published: July 09, 2025 by: CNBC
Sentiment: Positive
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
Published: July 08, 2025 by: Reuters
Sentiment: Positive
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.
Read More
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Published: July 07, 2025 by: Benzinga
Sentiment: Negative
Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company's stock has plummeted approximately 18% over the past month, reflecting recent challenges.
Read More
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding threats are overblown; FDA enforcement and strategic partnerships will redirect demand to branded Wegovy. An oral semaglutide approval later this year can help reignite share price momentum.
Read More
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Published: July 01, 2025 by: CNBC Television
Sentiment: Positive
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
6 International Stocks To buy in July
Published: June 27, 2025 by: 24/7 Wall Street
Sentiment: Positive
With over $5 trillion of new investment commitments to date, the U.S.
Read More
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Read More
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
Published: June 26, 2025 by: WSJ
Sentiment: Positive
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
Read More
Novo Nordisk ties up with WeightWatchers to sell Wegovy
Published: June 26, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1.
Read More
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
Published: June 26, 2025 by: PRNewsWire
Sentiment: Neutral
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing A new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® PLAINSBORO, N.J. , June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy® (semaglutide) injection 2.4 mg through a new collaboration with …
Read More
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
Read More
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
Read More
Hims & Hers: The Novo Nordisk Breakup Changes Nothing
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a GLP-1 play. HIMS' core value lies in its broad treatment offerings and disruptive model, not in partnerships with big pharma like NVO. Legal risks remain, but I believe HIMS is well-positioned to defend itself, and no legal action has been initiated by NVO yet.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406